Oxazolidinone antibacterial agents: development of the clinical candidates eperezolid and linezolid

Bibliography

• DAVIES J: Inactivation of antibiotics and the dissemina-tion of resistance genes. Science (1994) 264:375–382.
   PubMed Web of Science ®Google Scholar
• NIKAIDO H: Prevention of drug access to antibacterial targets: permeability barriers and active efflux. Science (1994) 264:382–388.
   PubMed Web of Science ®Google Scholar
• SPRATT BG: Resistance to antibiotics mediated by target alterations. Science (1994) 264:388–393.
   PubMed Web of Science ®Google Scholar
• SLEE AM, WUONOLA MA, MCRIPLEY RJ et al.: Oxazolidi-nones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob. Afflnts Chemother. (1987) 31:1791–1797.
   PubMed Web of Science ®Google Scholar
• DALY JS, ELIOPOULOS GM, WILLEY S, MOELLERING RC, Jr.: Mechanism of action and in vitro and in vivo activi-ties of S-6123, a new oxazolidinone compound. Antimi-crob. Agents Chemother. (1988) 32:1341–1346.
   Google Scholar
• DALY JS, ELIOPOULOS GM, REISZNER E, MOELLERING RC, Jr.: Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J. Antimicrob. Chemother. (1988) 21:721–730.
   Google Scholar
• EUSTICE DC, FELDMAN PA, SLEE AM: The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis. Biochem. Biophys. Res. Com-mun. (1988) 150:965–971.
   PubMed Web of Science ®Google Scholar
• EUSTICE DC, FELDMAN PA, ZAJAC I, SLEE AM: Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob. Agents Chemother. (1988) 32:1218–1222.
   PubMed Web of Science ®Google Scholar
• BARRY AL: ht vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents. Antimi-crob. Agents Chemother. (1988) 32:150–152.
   PubMed Web of Science ®Google Scholar
• BRUMFITT W, HAMILTON-MILLER JMT: In vitro microbio-logical activities of DuP 105 and DuP 721, novel syn-thetic oxazolidinones. j Antimicrob. Chemother. (1988) 21:711–720.
   PubMed Web of Science ®Google Scholar
• NEU HC, NOVELLI A, SAHA G, CHIN N-X: In vitro activitiesof two oxazolidinone antimicrobial agents, DuP 721 and DuP 105. Antimicrob. Agents Chemother. (1988) 32:580–583.
   PubMed Web of Science ®Google Scholar
• ZAJAC I, LAM GW, HOFFMAN HE, SLEE AM: Pharmacoki-netics of DuP 721, a new synthetic oxazolidinone an-tibacterial. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy New York (1987). Abstract 247.
   Google Scholar
• BRICKNER SJ, HUTCHINSON DK, BARBACHYN MR et al:
   Google Scholar
• ••Synthesis and antibacterial activity of U-100592 andU-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J. Med. Chem. (1996) 39:673–679.
   PubMed Web of Science ®Google Scholar
• Describes the synthesis of eperezolid and linezolid.
   Google Scholar
• BRICKNER SJ: Oxazolidinone antibacterial agents. Cur- rent Pharmaceutical Design (1996) 2:175–194.
   Google Scholar
• A comprehensive review of oxazolidinone synthesis and structure-activity relationships.
   Google Scholar
• SHINABARGER DL, MAROTTI KR, MURRAY RW et al: Inhibition of protein synthesis by the oxazolidinoneantibiotic U-100592. 96th Meeting of the American Society for Microbiology. New Orleans (1996). Abstract A-75. Describes the first evidence that eperezolid inhibits the initiation of protein synthesis in bacteria.
   Google Scholar
• UN AH, MURRAY RW, SCHAADT RD eta]: Oxazolidinones block translation initiation by binding to ribosomes th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1996). Abstract C101 The first study presenting evidence that eperezolid binds to the bacterial ribosome.
   Google Scholar
• BUYSSE JM, DEMYAN WF, DUNYAK DS eta]: Mutation of the AcrAB antibiotic efflux pump in Escherichia coli confers susceptibility to oxazolidinone antibiotics. 36th Interscience Conference on Antimicrobial Agents and Che-motherapy New Orleans (1996). Abstract C42.
   Google Scholar
• JONES RN, JOHNSON DM, ERWIN ME: In vitro antimicro- bial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob. Agents Chemother. (1996) 40:720–726.
   Google Scholar
• A comprehensive in vitro study including recommendations for disk-diffusion susceptibility testing.
   Google Scholar
• ZURENKO GE, YAGI BH, SCHAADT RD et al In vitro activities of U-100592 and U-100766, novel oxazolidi- none antibacterial agents. Antimicrob. Agents Chemother. (1996) 40:839–845 A comprehensive assessment of the in vitro antibacterial activity of eperezolid and linezolid.
   Google Scholar
• WATTS JL, SALMON SA, YANCEY RJ JR, FORD CW: In vitro activity of two oxazolidinone antimicrobial agents (U-100592 and U-100766) against Mycoplasma spp. 35th Interscience Conference on Antimicrobial Agents and Che-motherapy. San Francisco (1995). Abstract F220.
   Google Scholar
• YAGI BH, ZURENKO GE: In vitroactivity ofU-100766 and
   Google Scholar
• •U-100592, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria. Anaerobe Society of the Americas Congress on Anaerobic Bacteria and Anaerobic Infections. Chicago (1996). Abstract 45PP.
   Google Scholar
• An assessment of eperezolid and linezolid activity against a broad spectrum of anaerobic bacteria.
   Google Scholar
• ELIOPOULOS GM, WENNERSTEN CB, GOLD HS, MOELLER-ING RC, Jr.: In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob. Agents Chemother. (1996) 40:1745–1747.
   PubMed Web of Science ®Google Scholar
• KAATZ GW, SEO SM: In vitro activities of oxazolidinone compounds U-100592 and U-100766 against Staphylo-coccus aureus and Staphylococcus epidermidis. An-timicrob. Agents Chemother. (1996) 40:799–801.
   PubMed Web of Science ®Google Scholar
• MULAZIMOGLU L, DRENNING SD, YU VL: In vitroactivity of two novel oxazolidinones (U-100592 and U-100766), a new fluoroquinolone (trovafloxacin), and dalfo-pristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chem other. (1996) 40(10):2428–2430.
   PubMed Web of Science ®Google Scholar
• ZURENKO GE, YAGI BH, SCHAADT RD et al.: In vitro activities of U-100592 and U-100766, novel oxazolidi-none antibacterial agents. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco (1995). Abstract F216.
   Google Scholar
• FORD CVV, HAMEL JC, WILSON DM eta]: In vivo activities of U-100592 and U-100766, novel oxazolidinone antimi- crobial agents, against experimental bacterial infec-tions. Antimicrob. Agents Chemother. (1996) 40:1508-1513. A broad evaluation of the activities of eperezolid and linezolid in animal models.
   Google Scholar
• KLEMENS SP, SHARPE CA, CYNAMON MH: Activities of two novel oxazolidinones against M. tuberculosis (MTB) in a murine model. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco (1995). Abstract F228.
   Google Scholar
• BARBACHYN MR, HUTCHINSON DK, BRICKNER SJ eta].: Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem. (1996) 39:680–685.
   Google Scholar
• ANDES D, VESGA 0, BATTS D, CRAIG WA: Pharmacodynamic activity of an oxazolidinone in an animal infec-tion model. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1996). Abstract F233.
   Google Scholar
• Assessment of the key pharmacodynamic parameter for antibacterial efficacy.
   Google Scholar
• PIPER RC, LUND JE, DENLINGER RH et a].: One month preclinical oral and IV toxicity evaluation of U-100592, an oxazolidinone antibiotic, in beagle dogs and Spra-gue-Dawley rats. 35th Interscience Conference on Antimi-crobial Agents and Chemotherapy San Francisco (1995). Abstract F223.
   Google Scholar
• KOIKE S, MIURA H, NAKAMURA R, CHIBA K, MOE JB: Drug safety studies with a novel oxazolidinone, U-100766. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco (1995). Abstract F224.
   Google Scholar
• PAWSEY SD, HARRY JD, STALKER DJ: 1st administration of a new oxazolidinone antibiotic (U-100592) to man. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco (1995). Abstract F225.
   Google Scholar
• BATTS DH, STALKER DJ, PEEL BG et al.: U-100592 Phase
   Google Scholar
• •I, multiple-oral dose randomized, placebo-controlled, safety, tolerance and pharmacokinetics in healthy vol-unteers for 14.25 days using bulk drug in capsules. 35th Intel-science Conference on Antimicrobial Agents and Che-motherapy San Francisco (1995). Abstract F226.
   Google Scholar
• Describes the safety and pharmacokinetics of eperezolid in humans.
   Google Scholar
• PAWSEY SD, DALEY-YATES PT, WAJSZCZUK CP, STALKER
   Google Scholar
• •DJ: U-100766 safety, toleration and pharmacokinetics after oral and intravenous (IV) administration. 1st Euro-pean Congress of Chemotherapy Glasgow (1996). Abstract F151.
   Google Scholar
• Describes the safety and pharmacokinetics of linezolid in humans.
   Google Scholar
• PARK C-H, BRITELLI DR, WANG CL-J et al: Antibacterials. Synthesis and structure-activity studies of 3-ary1-2-oxooxazolidines. 4. Multiply-substituted aryl deriva-tives. J. Med. Chem. (1992) 35:1156–1165.
   Google Scholar
• SPANGLER SK, JACOBS MR, APPELBAUM PC: Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. (1996) 40:481–4.
   PubMed Web of Science ®Google Scholar
• MASON EO JR, LAMBERTH LB, KAPLAN SL: hi vftroactivi-ties of oxazolidinones U100592 and U-100766 against penicillin-resistant and cep hal os p or in-re sistant strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1996) 40:1039–1040.
   PubMed Web of Science ®Google Scholar